Juan Chen, Lili Fu, Mengjin Li, Kun Xie, Xinming Li, Xu-Jie Zhou, Li Yang, Liming Zhang, Cheng Xue, Zhiguo Mao
{"title":"慢性肾病脑源性神经营养因子表达降低:综合临床和实验证据。","authors":"Juan Chen, Lili Fu, Mengjin Li, Kun Xie, Xinming Li, Xu-Jie Zhou, Li Yang, Liming Zhang, Cheng Xue, Zhiguo Mao","doi":"10.3389/fmolb.2025.1627534","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Chronic kidney disease (CKD) is a progressive disorder characterized by declining renal function and systemic metabolic disturbances. Brain-derived neurotrophic factor (BDNF), a key member of the neurotrophic family, plays critical roles in neuronal function and muscular metabolism. However, the evidence and regulatory mechanisms underlying decreased BDNF levels in CKD remain inconclusive.</p><p><strong>Methods: </strong>This study systematically evaluated circulating BDNF alterations in CKD patients through a meta-analysis of clinical studies involving 1,549 participants, complemented by experimental validation in unilateral ureteral obstruction (UUO) mice and single-cell transcriptomic database analysis to investigate tissue-specific BDNF protein expression and regulatory patterns.</p><p><strong>Results: </strong>Meta-analysis confirmed significantly reduced circulating BDNF in CKD patients (WMD = -0.62 ng/mL, 95% CI [-0.98, -0.25], <i>P</i> < 0.001; <i>I</i> <sup><i>2</i></sup> = 87%). In 14-day UUO mice, renal immunohistochemistry (IHC) showed significantly reduced BDNF expression (<i>P</i> < 0.001), which was further validated by Western blot analysis demonstrating a progressive decline in BDNF protein levels from day 14 to day 21 post-obstruction. Single-cell mRNA sequencing further confirmed that <i>Bdnf</i> levels were lower in renal proximal tubule (PT) cells, macrophages (Mφ), and podocytes in UUO mice compared to normal controls, Additionally, <i>Bdnf-as</i>-a long non-coding RNA known to epigenetically repress BDNF-was significantly upregulated in proximal tubules of CKD patients based on human transcriptomic data. This upregulation was validated in UUO mice by qPCR, showing a time-dependent increase in <i>Bdnf-as</i> expression at days 14 and 18 post-obstruction.</p><p><strong>Conclusion: </strong>This study integrated meta-analysis, murine model validation, and single-cell transcriptomic profiling to demonstrate a significant reduction of BDNF in CKD. Furthermore, renal BDNF expression decreased locally, predominantly originating from proximal tubule cells, macrophages, and podocytes, possibly epigenetically inhibited by the upregulation of lnc RNA <i>Bdnf-as</i>.</p>","PeriodicalId":12465,"journal":{"name":"Frontiers in Molecular Biosciences","volume":"12 ","pages":"1627534"},"PeriodicalIF":3.9000,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12336020/pdf/","citationCount":"0","resultStr":"{\"title\":\"Decreased brain-derived neurotrophic factor expression in chronic kidney disease: integrated clinical and experimental evidence.\",\"authors\":\"Juan Chen, Lili Fu, Mengjin Li, Kun Xie, Xinming Li, Xu-Jie Zhou, Li Yang, Liming Zhang, Cheng Xue, Zhiguo Mao\",\"doi\":\"10.3389/fmolb.2025.1627534\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Chronic kidney disease (CKD) is a progressive disorder characterized by declining renal function and systemic metabolic disturbances. Brain-derived neurotrophic factor (BDNF), a key member of the neurotrophic family, plays critical roles in neuronal function and muscular metabolism. However, the evidence and regulatory mechanisms underlying decreased BDNF levels in CKD remain inconclusive.</p><p><strong>Methods: </strong>This study systematically evaluated circulating BDNF alterations in CKD patients through a meta-analysis of clinical studies involving 1,549 participants, complemented by experimental validation in unilateral ureteral obstruction (UUO) mice and single-cell transcriptomic database analysis to investigate tissue-specific BDNF protein expression and regulatory patterns.</p><p><strong>Results: </strong>Meta-analysis confirmed significantly reduced circulating BDNF in CKD patients (WMD = -0.62 ng/mL, 95% CI [-0.98, -0.25], <i>P</i> < 0.001; <i>I</i> <sup><i>2</i></sup> = 87%). In 14-day UUO mice, renal immunohistochemistry (IHC) showed significantly reduced BDNF expression (<i>P</i> < 0.001), which was further validated by Western blot analysis demonstrating a progressive decline in BDNF protein levels from day 14 to day 21 post-obstruction. Single-cell mRNA sequencing further confirmed that <i>Bdnf</i> levels were lower in renal proximal tubule (PT) cells, macrophages (Mφ), and podocytes in UUO mice compared to normal controls, Additionally, <i>Bdnf-as</i>-a long non-coding RNA known to epigenetically repress BDNF-was significantly upregulated in proximal tubules of CKD patients based on human transcriptomic data. This upregulation was validated in UUO mice by qPCR, showing a time-dependent increase in <i>Bdnf-as</i> expression at days 14 and 18 post-obstruction.</p><p><strong>Conclusion: </strong>This study integrated meta-analysis, murine model validation, and single-cell transcriptomic profiling to demonstrate a significant reduction of BDNF in CKD. Furthermore, renal BDNF expression decreased locally, predominantly originating from proximal tubule cells, macrophages, and podocytes, possibly epigenetically inhibited by the upregulation of lnc RNA <i>Bdnf-as</i>.</p>\",\"PeriodicalId\":12465,\"journal\":{\"name\":\"Frontiers in Molecular Biosciences\",\"volume\":\"12 \",\"pages\":\"1627534\"},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2025-07-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12336020/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in Molecular Biosciences\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://doi.org/10.3389/fmolb.2025.1627534\",\"RegionNum\":3,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Molecular Biosciences","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.3389/fmolb.2025.1627534","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:慢性肾脏疾病(CKD)是一种以肾功能下降和全身代谢紊乱为特征的进行性疾病。脑源性神经营养因子(BDNF)是神经营养家族的重要成员,在神经元功能和肌肉代谢中起着至关重要的作用。然而,CKD中BDNF水平下降的证据和调控机制仍不确定。方法:本研究通过对1549名参与者的临床研究进行meta分析,系统评估CKD患者循环BDNF的改变,辅以单侧输尿管梗阻(UUO)小鼠的实验验证和单细胞转录组数据库分析,研究组织特异性BDNF蛋白表达和调控模式。结果:荟萃分析证实CKD患者循环BDNF显著降低(WMD = -0.62 ng/mL, 95% CI [-0.98, -0.25], P < 0.001;i2 = 87%)。在第14天的UUO小鼠中,肾免疫组化(IHC)显示BDNF表达显著降低(P < 0.001), Western blot分析进一步证实了BDNF蛋白水平从梗阻后的第14天到第21天逐渐下降。单细胞mRNA测序进一步证实,与正常对照组相比,UUO小鼠肾近端小管(PT)细胞、巨噬细胞(Mφ)和足细胞中的Bdnf水平较低。此外,基于人类转录组学数据,Bdnf作为一种已知的表观遗传抑制Bdnf的长链非编码RNA,在CKD患者近端小管中显著上调。这种上调在UUO小鼠中通过qPCR验证,显示阻塞后14天和18天Bdnf-as表达呈时间依赖性增加。结论:该研究综合了荟萃分析、小鼠模型验证和单细胞转录组学分析,证明CKD患者BDNF显著降低。此外,肾BDNF的局部表达减少,主要来自近端小管细胞、巨噬细胞和足细胞,可能受到lnnc RNA BDNF -as上调的表观遗传抑制。
Decreased brain-derived neurotrophic factor expression in chronic kidney disease: integrated clinical and experimental evidence.
Background: Chronic kidney disease (CKD) is a progressive disorder characterized by declining renal function and systemic metabolic disturbances. Brain-derived neurotrophic factor (BDNF), a key member of the neurotrophic family, plays critical roles in neuronal function and muscular metabolism. However, the evidence and regulatory mechanisms underlying decreased BDNF levels in CKD remain inconclusive.
Methods: This study systematically evaluated circulating BDNF alterations in CKD patients through a meta-analysis of clinical studies involving 1,549 participants, complemented by experimental validation in unilateral ureteral obstruction (UUO) mice and single-cell transcriptomic database analysis to investigate tissue-specific BDNF protein expression and regulatory patterns.
Results: Meta-analysis confirmed significantly reduced circulating BDNF in CKD patients (WMD = -0.62 ng/mL, 95% CI [-0.98, -0.25], P < 0.001; I2 = 87%). In 14-day UUO mice, renal immunohistochemistry (IHC) showed significantly reduced BDNF expression (P < 0.001), which was further validated by Western blot analysis demonstrating a progressive decline in BDNF protein levels from day 14 to day 21 post-obstruction. Single-cell mRNA sequencing further confirmed that Bdnf levels were lower in renal proximal tubule (PT) cells, macrophages (Mφ), and podocytes in UUO mice compared to normal controls, Additionally, Bdnf-as-a long non-coding RNA known to epigenetically repress BDNF-was significantly upregulated in proximal tubules of CKD patients based on human transcriptomic data. This upregulation was validated in UUO mice by qPCR, showing a time-dependent increase in Bdnf-as expression at days 14 and 18 post-obstruction.
Conclusion: This study integrated meta-analysis, murine model validation, and single-cell transcriptomic profiling to demonstrate a significant reduction of BDNF in CKD. Furthermore, renal BDNF expression decreased locally, predominantly originating from proximal tubule cells, macrophages, and podocytes, possibly epigenetically inhibited by the upregulation of lnc RNA Bdnf-as.
期刊介绍:
Much of contemporary investigation in the life sciences is devoted to the molecular-scale understanding of the relationships between genes and the environment — in particular, dynamic alterations in the levels, modifications, and interactions of cellular effectors, including proteins. Frontiers in Molecular Biosciences offers an international publication platform for basic as well as applied research; we encourage contributions spanning both established and emerging areas of biology. To this end, the journal draws from empirical disciplines such as structural biology, enzymology, biochemistry, and biophysics, capitalizing as well on the technological advancements that have enabled metabolomics and proteomics measurements in massively parallel throughput, and the development of robust and innovative computational biology strategies. We also recognize influences from medicine and technology, welcoming studies in molecular genetics, molecular diagnostics and therapeutics, and nanotechnology.
Our ultimate objective is the comprehensive illustration of the molecular mechanisms regulating proteins, nucleic acids, carbohydrates, lipids, and small metabolites in organisms across all branches of life.
In addition to interesting new findings, techniques, and applications, Frontiers in Molecular Biosciences will consider new testable hypotheses to inspire different perspectives and stimulate scientific dialogue. The integration of in silico, in vitro, and in vivo approaches will benefit endeavors across all domains of the life sciences.